COVID-19 vaccine for children in India may be available by September, says AIIMS chief Randeep Guleria

-

Children in India can start receiving coronavirus vaccine shots as early as September, All India Institue of Medical Sciences, New Delhi Director, Dr Randeep Guleria said on Saturday.

Speaking to NDTV, Guleria said that there are a few vaccine candidates available that have been deemed safe for children. These include Pfizer, Bharat Biotech's Covaxin and Zydus Cadilla's ZyCoV-D shots.

Which vaccine candidates are in pipeline for use in children?

So far, no Covid vaccine for below 12-year-olds has been approved anywhere in the world while India is only vaccinating those who are 18 and above. However, a few vaccine candidates are in the pipeline.

  • While Pfizer already has US Food and Drug Administration's approval for use on children aged 12 to 17, it expects approval for use on children between 5 to 11 years of age by September. The company is also conducting trials on children of ages between 6 months to 11 years.
  • Russia's Sputnik V vaccine has started trials on children aged 12 to 17 years in Moscow, earlier this month.
  • Of the homegrown candidates, Bharat Biotech's Covaxin is undergoing trials on children at AIIMS Delhi. It is due to begin trial for the second dose of Covaxin on children between the age of 2-6 years by next week, while children between ages 6-12 years have already received the second shot and are being monitored for antibody response and reports of any vaccine-induced adverse events.
  • Zydus Cadila's vaccine for children is has concluded its clinical trial for the age group of 12 to 18.

However, Pune’s Serum Institute was denied permission to conduct trials of its Covovax vaccine on children between 2 to 17 years. The expert panel recommended that SII finish their adult trials first.

Guleria had in the past also advocated for reopening of schools highlighting that children have stronger resistance to serious disease even if they do contract the infection. Suggesting strongly that now it is high time that schools should reopen, Guleria said, "I personally feel that we should aggressively work on opening schools because it has really affected the young generation in terms of knowledge and especially the marginalised ones who can't go for online classes, they are suffering."



from Firstpost India Latest News https://ift.tt/3kLznQu
FP Staff

Comments

Post a Comment

Popular posts from this blog

Both COVID-19 vaccine doses needed for good protection against B16172 variant

-
It’s been a concerning few weeks in the UK, with the B16172 variant first taking hold and then spreading to become dominant. This more infectious form of the virus, initially identified in India, is what we’re now going to have to live with – unless it is out-competed by another variant in the future. Worryingly, experts had predicted that B16172 might be able to escape some of the effects of vaccines, which if true would threaten to derail the UK’s plans to finish lifting restrictions from the end of June. However, Public Health England (PHE) has looked at the ability of various variants to evade immunity and says that the UK’s vaccines remain effective against the variants circulating, including B16172. On the surface, this looks like good news. But delve a bit deeper, and things get more complicated, says Paul Hunter, professor of medicine at the University of East Anglia. PHE’s research found a little drop-off in protection against B16172 among people who were fully vaccinated.
Read more

New coronavirus variant emerge in India: How should our COVID response change?

-
Image
After genome sequencing of over 10,000 COVID-19 cases in India, researchers have discovered a new variant with two new mutations which may be better at evading the immune system. In 15-20 percent of samples from the Indian state of Maharashtra (the state accounting for 62 percent of cases in the country) a new, double mutation in key areas of the virus has been detected. These are now known as the E484Q and L452R mutations. What makes the variant different? Both these mutations are concerning because they are located in a key portion of the virus – the spike protein – that it uses to penetrate human cells. Spike proteins attach via a “receptor binding domain”, meaning the virus can attach to receptors in our cells. These new mutations include changes to the spike protein that make it a “better fit” for human cells. This means the virus can gain entry more easily and multiply faster. Given what we have seen with other similar mutations , it might also make it harder for our immu
Read more

Aditya L1 Mission: Spacecraft is nearing its final phase, says ISRO chief

-
Aditya L1 spacecraft is nearing its final phase, and manoeuvres to enter the L1 point are expected to be completed by January 7, 2024, according to ISRO Chairman S Somanath. “Aditya is on the way. I think it has reached almost its final phase,” the ISRO chief told PTI on the sidelines of an event organised at VSSC to commemorate the 60th year of the First Sounding Rocket Launch. Aditya L1, India’s first space-based mission to study the Sun, was successfully launched on September 2 from the Satish Dhawan Space Centre (SDSC) in Sriharikota. The spacecraft, after travelling about 1.5 million km from Earth over 125 days, is expected to be placed in a Halo orbit around the Lagrangian point L1, considered closest to the Sun. He said that the last preparations for the spacecraft’s entry into the L1 point are currently underway incrementally.”Possibly by January 7th, the final manoeuvres will be done for entering into the L1 point,” Somanath added. Among other tasks, it will capture and tr
Read more